Core Viewpoint - A class action securities lawsuit has been filed against Organon & Co. due to alleged securities fraud that negatively impacted investors between October 31, 2024, and April 30, 2025 [1] Group 1: Lawsuit Details - The lawsuit claims that Organon's management made overly positive statements while concealing material adverse facts about the company's capital allocation priorities, particularly regarding a significant debt reduction strategy following the acquisition of Dermavant [2] - As a result of these actions, Organon reduced its regular quarterly dividend by 70%, leading to a dramatic decline in stock price from $12.93 per share on April 30, 2025, to $9.45 per share on May 1, 2025, representing a drop of over 27% in just one day [2] Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until July 22, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving in this role [3] - Class members may be entitled to compensation without incurring any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky has a strong track record, having secured hundreds of millions of dollars for shareholders over the past 20 years and is recognized as one of the top securities litigation firms in the United States [4]

Core Viewpoint - Organon & Co. is facing a class action lawsuit due to significant changes in its dividend policy and alleged misleading statements regarding its financial health and business strategy [1][3]. Financial Performance - On May 1, 2025, Organon reported its Q1 2025 financial results, announcing a drastic reduction in its dividend payout from $0.28 to $0.02, reallocating funds towards debt reduction [2]. - Following this announcement, Organon's stock price dropped by $3.48, or 26.9%, closing at $9.45 per share on the same day [2]. Lawsuit Details - The class action complaint alleges that during the Class Period, Organon made materially false and misleading statements and failed to disclose adverse facts about its business and operations [3]. - Specific allegations include the misleading portrayal of the dividend payout as a priority while simultaneously implementing a debt reduction strategy that led to a more than 70% decrease in the quarterly dividend [3]. - The lawsuit claims that the positive statements made by the company regarding its business prospects lacked a reasonable basis and were materially misleading [3]. Legal Action - Investors who purchased Organon securities during the Class Period have until July 22, 2025, to file a lead plaintiff motion in the class action lawsuit [1][4].

Core Viewpoint - A class action lawsuit has been filed against Organon & Co. for alleged violations of federal securities laws, particularly concerning misleading statements about capital allocation and dividend payouts [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Organon concealed important information regarding its capital allocation priorities, specifically the future of its quarterly dividend payout [2]. - The company reported quarterly dividends as its "number one priority," which contradicted its debt reduction strategy, ultimately resulting in a 70% reduction in dividends [2]. Group 2: Investor Information - Shareholders who purchased Organon's securities between October 31, 2024, and April 30, 2025, are encouraged to contact the DJS Law Group before July 22, 2025, to participate in the lawsuit [1].

Core Viewpoint - A class action securities lawsuit has been filed against Organon & Co. due to alleged securities fraud that negatively impacted investors between October 31, 2024, and April 30, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Organon's management made overly positive statements while concealing material adverse facts about the company's capital allocation priorities, particularly regarding a significant debt reduction strategy following the acquisition of Dermavant [2]. - As a result of these actions, Organon reduced its regular quarterly dividend by 70%, leading to a dramatic decline in stock price from $12.93 per share on April 30, 2025, to $9.45 per share on May 1, 2025, representing a drop of over 27% in just one day [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until July 22, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving in this role [3]. - Class members may be entitled to compensation without incurring any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Organon & Co. due to misleading statements regarding its capital allocation strategy, particularly concerning quarterly dividends and debt reduction following the acquisition of Dermavant [3][5]. Group 1: Legal Investigation and Class Action - A federal securities class action has been filed against Organon, with a deadline of July 22, 2025, for investors to seek the role of lead plaintiff [3]. - Investors who purchased Organon securities between October 31, 2024, and April 30, 2025, are encouraged to discuss their legal rights with Faruqi & Faruqi [1][3]. Group 2: Financial Impact and Stock Performance - Organon’s stock price experienced a significant decline, dropping from $12.93 per share on April 30, 2025, to $9.45 per share on May 1, 2025, representing a decrease of over 27% in one day [6]. - The misleading statements regarding capital allocation led to shareholders purchasing securities at artificially inflated prices, which contributed to the stock's sharp decline [5]. Group 3: Company’s Capital Allocation Strategy - Defendants provided positive reassurances about Organon's commitment to regular quarterly dividends as a "1 capital allocation priority" while concealing the prioritization of debt reduction [5]. - The company’s decision to reduce the regular quarterly dividend by 70% was not disclosed to investors, impacting their investment decisions [5].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Organon & Co. regarding a class action lawsuit due to misleading statements and a significant reduction in quarterly dividends, which led to a sharp decline in stock price [1][3]. Summary by Relevant Sections Class Action Details - Shareholders who purchased Organon shares between October 31, 2024, and April 30, 2025, are encouraged to contact the firm for potential lead plaintiff appointment [1][3]. - The lawsuit alleges that Organon provided overly positive statements while concealing material adverse facts about its capital allocation priorities, particularly regarding debt reduction after the acquisition of Dermavant [3]. Financial Impact - Following the announcement of a 70% decrease in the regular quarterly dividend, Organon's stock price plummeted from $12.93 per share on April 30, 2025, to $9.45 per share on May 1, 2025, marking a decline of over 27% in just one day [3]. Next Steps for Shareholders - The deadline for shareholders to register for the class action is July 22, 2025, and those who register will receive updates through a portfolio monitoring software [4]. - Participation in the case does not incur any cost or obligation for the shareholders [4]. Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud, aiming to ensure responsible business practices [5].

Core Viewpoint - The Organon class action lawsuit alleges that the company and its executives made misleading statements regarding capital allocation and dividend payouts, leading to significant financial losses for investors [1][4]. Group 1: Lawsuit Details - The lawsuit, titled Hauser v. Organon & Co., seeks to represent purchasers of Organon securities and claims violations of the Securities Exchange Act of 1934 [1]. - Allegations include the concealment of material information about Organon's capital allocation priorities and a drastic reduction of the quarterly dividend payout by over 70% [4]. - On May 1, 2025, Organon announced a reduction in its dividend payout from $0.28 to $0.02, resulting in a stock price drop of more than 27% [5]. Group 2: Lead Plaintiff Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Organon securities during the class period to seek appointment as lead plaintiff [6]. - The lead plaintiff represents the interests of all class members and can select a law firm for litigation [6]. Group 3: Company Background - Organon develops health solutions through prescription therapies and medical devices [3]. - Robbins Geller Rudman & Dowd LLP, the law firm handling the case, is recognized for securing substantial monetary relief for investors in securities fraud cases [7].

Core Viewpoint - A lawsuit has been filed against Organon & Co. and its senior executives for potential violations of federal securities laws, particularly related to misleading statements about dividend policies following a significant acquisition [1][2][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the District of New Jersey, under the case caption Hauser v. Organon & Co., et al., No. 25-cv-05322, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [2]. - Investors have until July 22, 2025, to request to be appointed to lead the case [2]. Group 2: Company Background and Acquisition - Organon is a global healthcare company focused on women's health, known for rewarding shareholders with dividends [3]. - In October 2024, Organon completed a $1.2 billion acquisition of Dermavant, a biopharmaceutical company, which increased its debt [3]. Group 3: Dividend Policy and Stock Performance - Following the acquisition, Organon assured investors it would maintain its dividend, which was stated as its "1 capital allocation priority" [3]. - On May 1, 2025, Organon announced a drastic cut in its dividend payout from $0.28 per share to $0.02 per share, citing a shift in capital allocation priorities towards debt reduction [4]. - This announcement led to a significant decline in Organon's stock price, dropping approximately 27% from $12.93 per share on April 30, 2025, to $9.45 per share on May 1, 2025 [4].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Organon & Co. regarding a class action lawsuit due to allegations of misleading statements and a significant reduction in quarterly dividends, which led to a sharp decline in the company's stock price [1][2]. Group 1: Allegations and Impact - The class period for the allegations is from October 31, 2024, to April 30, 2025 [2]. - Defendants allegedly provided overly positive statements while concealing material adverse facts about Organon's capital allocation priorities, particularly regarding debt reduction after the acquisition of Dermavant [2]. - Following the revelation of these issues, Organon's stock price plummeted from $12.93 per share on April 30, 2025, to $9.45 per share on May 1, 2025, marking a decline of over 27% in just one day [2]. Group 2: Class Action Details - Shareholders are encouraged to register for the class action by the deadline of July 22, 2025, to potentially become lead plaintiffs [3]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the case lifecycle [3]. - Participation in the case incurs no cost or obligation for shareholders [3]. Group 3: Law Firm's Mission - The Gross Law Firm aims to protect investors' rights against deceit, fraud, and illegal business practices, emphasizing the importance of responsible corporate behavior [4]. - The firm seeks recovery for investors who suffered losses due to misleading statements or omissions that artificially inflated stock prices [4].

Core Viewpoint - Investors in Organon & Co. have the opportunity to lead a securities fraud class action lawsuit due to undisclosed information regarding dividend payouts and debt reduction strategies [1][2]. Summary by Relevant Sections Lawsuit Details - The lawsuit alleges that from October 31, 2024, to April 30, 2025, Organon failed to disclose that its reported commitment to dividend payouts was undermined by a new debt reduction strategy, resulting in a more than 70% decrease in quarterly dividends [2]. - It is claimed that Organon prioritized debt reduction following its acquisition of Dermavant, which was not communicated to investors [2]. - The positive statements made by the company regarding its business and prospects were misleading and lacked a reasonable basis during the relevant period [2]. Participation Information - Investors who suffered losses in Organon & Co. are encouraged to participate in the ongoing securities fraud lawsuit before the lead plaintiff deadline of July 22, 2025 [2]. - Interested parties can contact the Law Offices of Frank R. Cruz for more information or to learn about their rights regarding this matter [3][4].